ES2708843T3 - Alfa-galactosidasa estabilizada y usos de la misma - Google Patents

Alfa-galactosidasa estabilizada y usos de la misma Download PDF

Info

Publication number
ES2708843T3
ES2708843T3 ES16173953T ES16173953T ES2708843T3 ES 2708843 T3 ES2708843 T3 ES 2708843T3 ES 16173953 T ES16173953 T ES 16173953T ES 16173953 T ES16173953 T ES 16173953T ES 2708843 T3 ES2708843 T3 ES 2708843T3
Authority
ES
Spain
Prior art keywords
gal
galactosidase
activity
bis
nhs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16173953T
Other languages
English (en)
Spanish (es)
Inventor
Avidor Shulman
Ilya Ruderfer
Tehila Ben-Moshe
Talia Shekhter
Yaniv Azulay
Yoseph Shaaltiel
Tali Kizhner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protalix Ltd
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Application granted granted Critical
Publication of ES2708843T3 publication Critical patent/ES2708843T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
ES16173953T 2010-03-02 2011-03-02 Alfa-galactosidasa estabilizada y usos de la misma Active ES2708843T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434499P 2011-01-20 2011-01-20
US201161434503P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
ES2708843T3 true ES2708843T3 (es) 2019-04-11

Family

ID=44121635

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16173953T Active ES2708843T3 (es) 2010-03-02 2011-03-02 Alfa-galactosidasa estabilizada y usos de la misma
ES14195875.1T Active ES2606532T3 (es) 2010-03-02 2011-03-02 Alfa-galactosidasa estabilizada y usos de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14195875.1T Active ES2606532T3 (es) 2010-03-02 2011-03-02 Alfa-galactosidasa estabilizada y usos de la misma

Country Status (23)

Country Link
EP (3) EP2542675B1 (enExample)
JP (2) JP5758920B2 (enExample)
KR (1) KR101928403B1 (enExample)
CN (1) CN102933707B (enExample)
AU (1) AU2011222452B2 (enExample)
BR (1) BR112012022029B1 (enExample)
CA (1) CA2791461C (enExample)
DK (1) DK2865751T3 (enExample)
ES (2) ES2708843T3 (enExample)
FI (1) FIC20230032I1 (enExample)
FR (1) FR23C1041I2 (enExample)
HR (1) HRP20200428T1 (enExample)
HU (2) HUE030959T2 (enExample)
IL (2) IL221741A (enExample)
IN (1) IN2012MN02262A (enExample)
NL (1) NL301249I2 (enExample)
NO (1) NO2023041I1 (enExample)
NZ (2) NZ623294A (enExample)
PL (1) PL2865751T3 (enExample)
SG (2) SG183558A1 (enExample)
SI (1) SI2865751T1 (enExample)
WO (1) WO2011107990A1 (enExample)
ZA (1) ZA201206725B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
DK2865751T3 (en) * 2010-03-02 2017-01-09 Protalix Ltd Stabilized alpha-galactosidase and uses thereof
EP2665814B1 (en) * 2011-01-20 2017-05-17 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
AU2016232149B2 (en) 2015-03-17 2021-09-23 eleva GmbH Glycosylated lysosomal proteins, method of production and uses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
EP4321212A3 (en) * 2017-06-07 2024-05-15 Amano Enzyme Inc. Lactase bulk powder and lactase preparation
MY207075A (en) 2018-12-20 2025-01-28 Codexis Inc Human alpha-galactosidase variants
TW202146648A (zh) * 2020-02-28 2021-12-16 美商克迪科思股份有限公司 人類α-半乳糖苷酶變異體
JP7833461B2 (ja) 2020-11-03 2026-03-19 プロタリクス リミテッド 修飾ウリカーゼ及びその使用
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
MX2023005580A (es) * 2020-11-13 2023-05-29 Hanmi Pharmaceutical Co Ltd Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de enfermedades renales provocadas por o acompa?adas de la enfermedad de fabry.
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
US12703857B2 (en) 2023-02-02 2026-08-11 Protalix Ltd. Methods of treating diseases associated with elevated uric acid
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DK1009759T3 (da) * 1997-09-05 2008-08-04 Altus Pharmaceuticals Inc Carbohydrat-tværbundne glycoproteinkrystaller
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
CA2369869C (en) 1999-04-02 2008-06-10 Ajinomoto Co., Inc. Process for producing subunit peptide originating in polymer protein
DK1523548T3 (da) 2002-05-15 2010-05-10 Agricultural Res Org Polynukleotidsekvenser, som koder for alkaliske alfa-galactosidaser, og fremgangsmåder til anvendelse heraf
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
JP4368925B2 (ja) * 2005-11-18 2009-11-18 財団法人 東京都医学研究機構 基質特異性を変換した新規高機能酵素
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
DK2865751T3 (en) * 2010-03-02 2017-01-09 Protalix Ltd Stabilized alpha-galactosidase and uses thereof

Also Published As

Publication number Publication date
BR112012022029B1 (pt) 2022-10-11
EP2542675B1 (en) 2014-12-17
NL301249I2 (nl) 2023-12-14
ZA201206725B (en) 2013-06-26
PL2865751T3 (pl) 2017-03-31
JP5871999B2 (ja) 2016-03-01
SG183558A1 (en) 2012-10-30
EP3088514B1 (en) 2018-11-28
CN102933707B (zh) 2015-09-30
EP2865751B1 (en) 2016-09-14
EP2542675A1 (en) 2013-01-09
KR20130056216A (ko) 2013-05-29
SG10201502609QA (en) 2015-05-28
IL253249A (en) 2019-08-29
CA2791461A1 (en) 2011-09-09
NO2023041I1 (no) 2023-11-01
EP2865751A1 (en) 2015-04-29
ES2606532T3 (es) 2017-03-24
KR101928403B1 (ko) 2018-12-14
AU2011222452B2 (en) 2015-09-03
WO2011107990A1 (en) 2011-09-09
IL253249B (en) 2020-08-31
CN102933707A (zh) 2013-02-13
IN2012MN02262A (enExample) 2015-06-12
EP3088514A1 (en) 2016-11-02
BR122014021216A2 (pt) 2021-06-01
RU2604795C2 (ru) 2016-12-10
BR112012022029A2 (pt) 2021-05-18
SI2865751T1 (sl) 2017-01-31
RU2012141651A (ru) 2014-04-10
HK1180720A1 (en) 2013-10-25
NZ623294A (en) 2015-10-30
HUS2300038I1 (hu) 2023-11-28
CA2791461C (en) 2019-10-22
FR23C1041I1 (enExample) 2023-12-29
DK2865751T3 (en) 2017-01-09
JP2014237694A (ja) 2014-12-18
NL301249I1 (enExample) 2023-11-08
IL221741A (en) 2017-07-31
FIC20230032I1 (fi) 2023-11-02
HUE030959T2 (en) 2017-06-28
JP2013520986A (ja) 2013-06-10
AU2011222452A1 (en) 2012-09-27
JP5758920B2 (ja) 2015-08-05
FR23C1041I2 (fr) 2024-08-02
HRP20200428T1 (hr) 2020-06-12
NZ602317A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
ES2606532T3 (es) Alfa-galactosidasa estabilizada y usos de la misma
US12385026B2 (en) Stabilized alpha-galactosidase and uses thereof
US10907142B2 (en) Oligosaccharides comprising an aminooxy group and conjugates thereof
US20120328589A1 (en) Glucocerebrosidase multimers and uses thereof
CN106110309A (zh) α ‑半乳糖苷酶缺陷的治疗
HK1180720B (en) Stabilized alpha-galactosidase and uses thereof
BR122014021216B1 (pt) Composição farmacêutica compreendendo uma estrutura de proteína multimérica